Adrienne Asch: A Career at the Intersection of Bioethics and Disability Studies
By Sara Bergstresser,
Voices in Bioethics
| 03. 12. 2014
The first time I heard Adrienne Asch speak, she had assumed her role as a respected and influential member of the Disability Studies field. Later, as a student of Bioethics, I discovered that she was also a respected and influential Bioethicist. Who was this scholar with such expertise in two fields, and why did her contribution to each field have to be discovered separately? Asch passed away in November of 2013. Widely missed and memorialized in these two fields, I realized that there must be a third form of recognition for her pioneering work at the intersection of Disability Studies and Bioethics.
Asch was born in New York in 1946. Born premature, she developed retinopathy from too much oxygen in her incubator, thus losing her vision (Roberts 2013). Asch’s own difficulty in finding employment after graduating from Swarthmore College with a Bachelor’s degree in Philosophy made her keenly aware of disability as a civil rights issue (Fox 2013). She went on to study Social Work and Social Psychology at Columbia University and in 2005, she was recruited to direct the...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...